Home
    Disclaimer
    ← Back to MiPT
    MiPT molecular structure

    MiPT Stats & Data

    Psychedelic Research-chemical
    N-methyl-n-isopropyltryptamine
    NPS DataHub
    MW216.33
    FormulaC14H20N2
    CAS96096-52-5
    IUPACN-[2-(1H-indol-3-yl)ethyl]-N-methylpropan-2-amine
    SMILESCC(C)N(C)CCc1cnc2ccccc12
    InChIKeyKTQJVAJLJZIKKD-UHFFFAOYSA-N
    Tryptamines; 2020/5.1 Indol-3-alkylamine; 2021/5.1 Indol-3-alkylamine; 2022/5.1 Indol-3-alkylamine
    Chemical Class Phenethylamine
    Psychoactive Class Psychedelic

    Effect Profile

    Curated + 22 Reports
    Psychedelic 6.1

    Strong visuals with mild auditory effects and body load, low headspace

    Visual Intensity×3
    103.8
    Headspace Depth×3
    35.4
    Auditory Effects×1
    4
    Body Load / Somatic Effects×1
    43.1
    Catalog BlueLight
    Based on reports from:
    TiHKAL TiHKAL #47: MIPT Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki MiPT

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Insufflated
    0-1 minutes
    3.0-5.0 hours
    1.0-6.0 hours
    Oral
    30-45 minutes
    2.0-5.0 hours
    1.0-6.0 hours
    Smoked
    0-1 minutes
    2.0-3.0 hours
    1.0-6.0 hours

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1h Half tolerance 10d Baseline ~14d

    Cross-Tolerances

    LSD
    80% ●○○
    Psilocybin
    85% ●○○
    Psilocin
    85% ●○○
    Mescaline
    65% ●○○
    DMT
    85% ●○○
    5-MeO-DMT
    85% ●○○
    2C-B
    65% ●○○
    2C-E
    65% ●○○

    Experience Report Analysis

    Erowid BlueLight
    14 Reports
    1998–2021 Date Range
    7 With Age Data
    19 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid + Bluelight

    Effects aggregated from 22 experience reports (14 Erowid + 8 Bluelight)

    22 Reports
    59 Effects Detected
    38 Positive
    10 Adverse
    11 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 38

    Contentment 75.0% 75%
    Music Enhancement 59.1% 89%
    Emotional Openness 50.0% 80%
    Introspection 45.4% 77%
    Visual Trails 37.5% 73%
    Analysis Enhancement 37.5% 78%
    Brightness Enhancement 37.5% 78%
    Color Enhancement 36.4% 80%
    Stimulation 36.4% 80%
    Euphoria 36.4% 82%
    Empathy 36.4% 80%
    Focus Enhancement 36.4% 72%
    Body High 36.3% 81%
    Tactile Enhancement 31.8% 75%
    Tingling 25.0% 75%
    Closed-Eye Visuals 25.0% 80%
    Peripheral Imagery 25.0% 75%
    Visual Sharpening 25.0% 75%
    Awe 25.0% 75%
    Appetite Increase 25.0% 72%

    Adverse Effects 10

    Anxiety 57.1% 70%
    Nausea 36.4% 78%
    Muscle Tension 21.4% 70%
    Confusion 21.4% 70%
    Headache 18.2% 70%
    Vomiting 12.5% 70%
    Body Load 12.5% 85%
    Tension 12.5% 75%
    Tremor 12.5% 75%
    Dizziness 12.5% 65%

    Real-World Dose Distribution

    62K Doses

    From 18 individual dose entries

    Oral (n=12)

    Median: 24.5mg 25th: 20.0mg 75th: 42.5mg 90th: 63.5mg
    mg/kg median: 0.38 mg/kg 75th: 0.564

    Form / Preparation

    Most common forms and preparations reported

    Redose Patterns

    Redosing behavior across 10 reports

    30.0% Redosed
    1.4 Avg Doses
    4m Median Interval
    Read full reports on Erowid →
    ← Back to MiPT